A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
Yeah, should be interesting. George popped up on a NASEM meeting last week and it was pretty interesting to get his take. A little different than here in the US... I say we just make the whole of Florida a challenge trial :wink:
-
I am talking to Wellcome Vaccines dept tomorrow about challenge trials. They are considering which stocks to manufacture. I am not that sure what to tell them other than a basal D614G.
-
Yeah, NIAID asked us about getting an isolate from a "mild infection"... Well, mild, severe, moderate, chances are they're all the same. I agree on getting something as basal on the tree as possible (that's assuming D614G _does not_ show resistance to neutralization - which is a real concern (e.g., GP A82V in Ebola does that).
-
Jeremy's preprint suggests it is sensitive to ABs
-
2020-07-23 08:45
Andrew Rambaut
But I guess the point is it is the dominant form and will remain so.
-
The UK has been playing hard and loose with viruses in the past, so I wouldn't be surprised if we'd see challenge trials from them. IMO, this virus is much too dangerous with too many uncertain long-term effects to deliberately infect people - especially given the HUGE number of cases we have in this country.
-
Yeah, everything is basically D614G by now, so that's kinda the virus we need to make sure the vaccine works against - but I'm not really concerned there's a difference between Doug and Dougless here.
-
I agree that it is probably unnecessary - just try the vaccine.
-
Let's just immunize Florida and see what happens.... :smiling_imp: